| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/30/2004 | US20040266675 Transgenic aniomal nmodels; screening; administering peptide |
| 12/30/2004 | US20040266671 Orally administered peptides synergize statin activity |
| 12/30/2004 | US20040266663 Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and bruch's membrane (BM) |
| 12/30/2004 | US20040266661 Method for reducing hypertension and heart failure |
| 12/30/2004 | US20040266659 Administering acetylcholinesterase inhibitors |
| 12/30/2004 | US20040266652 Mixture of modified polyether and another nonionic surfactant; concentrates |
| 12/30/2004 | US20040266634 Adhesion inhibition of moulds |
| 12/30/2004 | US20040266025 Screening and treatment methods for prevention of preterm delivery |
| 12/30/2004 | US20040265976 Antigen and lysine acylated protein; cytokines; drug screening; liquid chromatography |
| 12/30/2004 | US20040265968 Tissue plasminogen activator-like protease |
| 12/30/2004 | US20040265958 that hydrolyzes fatty amides such as cis-9,10-octadecenoamide to neutralize the soporific activity of the fatty amides; enzyme inhibitors for use in treating sleep disorders |
| 12/30/2004 | US20040265948 Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters |
| 12/30/2004 | US20040265936 In gram-negative host cells; immunogenic epitopes from herpes virus; cytokines; interleukins; interferons; tumour necrosis factors; solid phase synthesis; homologous recombination |
| 12/30/2004 | US20040265927 Phospho-amino acid end groups interact with receptors on antigen-presenting cells; for treatment of T-cell mediated disorders (autoimmune conditions), inflammatory disorders, neurodegenerative disorders, and endothelial dysfunction disorders |
| 12/30/2004 | US20040265913 Tumor necrosis factors (TNF); humanized/chimeric monoclonal antibodies; fab fragments; hybridomas, host cells, Chinese Hamster Ovary cells |
| 12/30/2004 | US20040265898 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| 12/30/2004 | US20040265847 Administering zinc binding agent (sodium citrate) to modulate interaction within central nervous system between zinc and/or heparin with amyloid precursor proteins |
| 12/30/2004 | US20040265825 Methods and compositions for diagnosing and treating a subject having depression |
| 12/30/2004 | US20040265791 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products |
| 12/30/2004 | US20040265466 Oil composition |
| 12/30/2004 | US20040265462 Nutritional supplement |
| 12/30/2004 | US20040265427 Novel non-antibiotic strategy against ogip infections based on an activated cereal product or ferric quinate |
| 12/30/2004 | US20040265426 Process for producing miso |
| 12/30/2004 | US20040265400 Compositions for enhancing sexual responsiveness |
| 12/30/2004 | US20040265396 comprises zinc oxide, calcium channel blocker (3,5-pyridinedicarboxylic acid or nifedipine), and fat-soluble vitamins (vitamins A, D, E, K) admixed with antibacterial and antifungal agents; administered orally or topically |
| 12/30/2004 | US20040265395 Device for delivery of reducing agents to barrier membranes |
| 12/30/2004 | US20040265391 Method of treating acute myocardial infarction |
| 12/30/2004 | US20040265389 Degradable gel and method for producing the same |
| 12/30/2004 | US20040265388 Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| 12/30/2004 | US20040265382 Methylsulfonylphenyl or phenylsulfonamide derivatives having ring selected from cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine; celecoxib and rofecoxib; administered for pain; oral drug delivery |
| 12/30/2004 | US20040265381 Antispasmodic agent spaced drug delivery system comprising an immediate release oxybutynin or salts and excipient; and a timed pulse release oxybutynin; urinary incontinence therapy |
| 12/30/2004 | US20040265379 Administering 1900 to 2600 mg amoxycillin and an amount of potassium clavulanate such that the weight ratio of amoxycillin to clavulanate is 2:1 to 20:1, at a dosage regiment/interval of about 12 hours; pharmacokinetics; time release |
| 12/30/2004 | US20040265376 Orally deliverable; enhanced bioavailability; encapsulated in dissolution resistant material |
| 12/30/2004 | US20040265371 Hemostatic devices and methods of making same |
| 12/30/2004 | US20040265370 Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors |
| 12/30/2004 | US20040265369 Compounds that inhibit caspase activity for treating glaucoma |
| 12/30/2004 | US20040265364 Transdermal mixture for pain relief includes amitriptyline, clonidine, ketamine and antiinflammatory agent in pentravan gel; may contain local anesthetic lidocaine or EMLA; analgesics |
| 12/30/2004 | US20040265363 Transdermal therapeutic system provided with improved long-term carrying comfort |
| 12/30/2004 | US20040265362 Adhesive, skin and/or nail permeation enhancer; drug contained in contact layer; and binders, crosslinking agents, softeners, solvents, fillers and/or antioxidants; occlusive backing; fungal infection treatment of onychomycosis |
| 12/30/2004 | US20040265359 Oral delivery formulations of L-glutamine |
| 12/30/2004 | US20040265358 Modified methionine rich food products and process for their manufacture |
| 12/30/2004 | US20040265357 Combination of liponic acid and glutamine in food and pharmaceutical products |
| 12/30/2004 | US20040265353 Delivering benzodiazepine drug comprising alprazolam, lorazepam, clonazepam, or midazolam; forming a depot beneath skin surface; attenuates panic attack if delivered into systemic circulation; applying microwave, exothermic, or electric heat to skin surface |
| 12/30/2004 | US20040265351 Depositing within a localized tissue region a immune response modifier (IRM) depot preparation that provides an extended residence time within the localized tissue region; controlled drug delivery; synergistic; potentiation |
| 12/30/2004 | US20040265350 Ceramic carrier comprising interconnected skeleton of scaffolding and struts having pores; low density; time-release agents; fibroblast-, or transforming growth factors; bone morphogenic proteins, somatotrophin; antibiotics, vitamins, proteins, hormones, radiopacity agents |
| 12/30/2004 | US20040265345 Topically applied to treat skin damage, such as contact dermatitis, atopic dermatitis, xerosis, eczema, rosacea, seborrhea, psoriasis, and thermal and radiation burns; may include tyrosine, ascorbyl palmitate, glycolic acid, and/or folic acid |
| 12/30/2004 | US20040265327 Method of immunomodulation using thione-forming disulfides |
| 12/30/2004 | US20040265323 Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin A3), inhibitors thereof and methods of use thereof |
| 12/30/2004 | US20040265320 Administering a compound selected from 3-O-(3',3'-dimethylsuccinyl) betulinic acid, 3-O-(3',3'-dimethylsuccinyl) betulin, 3-O-(3',3'-dimethylglutaryl) betulin, 3-O-(3',3'-dimethylsuccinyl) dihydrobetulinic acid, 3-O-(3',3'-dimethylglutaryl) betulinic acid, (3',3'-dimethylglutaryl) dihydrobetulinic acid |
| 12/30/2004 | US20040265319 Geranyl-geranyl acetone as an active ingredient for treating influenza virus infection |
| 12/30/2004 | US20040265316 An antibody which specifically binds to a Fhit (fragile histidine triad) protein or derivative |
| 12/30/2004 | US20040265302 Preventing airway mucus production by administration of EGF-R antagonists |
| 12/30/2004 | US20040265291 Compositions and methods for restoring bacterial flora |
| 12/30/2004 | US20040265286 Method of lethally sensitizing human and animal cells |
| 12/30/2004 | US20040265284 Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains |
| 12/30/2004 | US20040265276 Medicinal combination useful for in vivo exogenic transfection and expression |
| 12/30/2004 | US20040265268 cell growth enhancers to increase growth rate of skin cells, nutrients to support log phase growth of skin cells, extracellular matrix proteins, stimulators of extracellular matrix proteins, penetration enhancers; wound healing |
| 12/30/2004 | US20040265244 nitrosyl-containing organometallic compound such as nitroprusside in dissolvable film decomposes at body temperature and in the presence of light to release *NO from the coating in an amount effective to prevent gingival and other oral mucosal diseases |
| 12/30/2004 | US20040265242 Administering drug to the respiratory tract of patient in a lower dosage than orally; treating Parkinson's or Alzheimer's disease; sleep, attention deficit hyperactivity, bipolar, and psychological disorders; headaches, antiepileptic agents; rescue therapy for a panic attack |
| 12/30/2004 | US20040265241 Methods for the inhalation administration of antibiotics |
| 12/30/2004 | US20040265239 Buccal, polar and non-polar spray containing zolpidem |
| 12/30/2004 | US20040265238 Inhalable formulations for treating pulmonary hypertension and methods of using same |
| 12/30/2004 | US20040265232 [18F]-furanosylpurine derivatives and uses thereof |
| 12/30/2004 | US20040265231 Use of antioxidants to mitigate radioimmunotherapy-induced radiation toxicity |
| 12/30/2004 | US20040265228 biomarkers for medicinal radioimaging such as Positron Emission Tomography; 4-Anilinoquinazolines |
| 12/30/2004 | US20040264421 Cell station, radio communication system, communication control method of cell station, and method of building radio communication network |
| 12/30/2004 | US20040261190 Hydrazono-malonitriles |
| 12/30/2004 | DE3745094B4 New stable hydrate of 7-butenoyl:amino- cephalosporin derivs. - esp. formulated in soft gelatin capsules sealed with gelatin layer |
| 12/30/2004 | DE19850830B4 Verfahren zur Herstellung einer Lösung, insbesondere einer Dialyse- oder Infusionslösung A process for preparing a solution, in particular dialysis or infusion a solution |
| 12/30/2004 | DE10326347A1 Agent for prophylaxis or therapy of coccidial infections or performance improvement in animals, comprising sorbic acid or its salt and omega-fatty acid, preferably added to feed or drinking water |
| 12/30/2004 | DE10326346A1 Verwendung von Sorbinsäure zur Vermeidung von bakteriellen Infektionen und als Leistungsförderer bei Tieren Use of sorbic acid for the prevention of bacterial infections and as growth promoters in animals |
| 12/30/2004 | DE10325829A1 Derivate natürlicher, halbsynthetischer und syntetischer Lipide aus der Gruppe der Ceramide und der Sphingosine und ihre Verwendung als Therapeutica in der Medizin, speziell in der Dermatologie Derivatives of natural, semisynthetic and SYNTHETIC lipids from the group of ceramides and sphingosines and their use as therapeutic agents in medicine, especially in dermatology |
| 12/29/2004 | WO2004113920A1 Screening method for substances binding to merozoite surface protein-1/42 |
| 12/29/2004 | WO2004113810A1 Process for increasing liquid extraction from fabrics |
| 12/29/2004 | WO2004113564A1 Method for investigating cytosine methylation in dna sequences by means of triplex-forming oligomers |
| 12/29/2004 | WO2004113451A1 Product of coprecipitation of sparingly soluble substance and water-soluble polymer and process for producing the same |
| 12/29/2004 | WO2004113424A1 Method for preparing coprecipitate of substance sparingly soluble in water and polymer soluble in water |
| 12/29/2004 | WO2004113359A1 Pyrazole derivative, drug composition containing the same and production intermediate therefor |
| 12/29/2004 | WO2004113343A1 Tricyclic triazolobenzazepine derivative produced as novel crystalline substance |
| 12/29/2004 | WO2004113340A1 Novel imidazopyridine compound iii with therapeutic effect |
| 12/29/2004 | WO2004113339A1 Novel imidazopyridine compound ii with therapeutic effect |
| 12/29/2004 | WO2004113338A1 Novel imidazopyridine compound i with therapeutic effect |
| 12/29/2004 | WO2004113337A1 Convergent synthesis of a garft inhibitor containing a methyl substitute thiophene core and a tetrahydropyrido`2,3-d! pyrimidine ring system and intermediates therefor |
| 12/29/2004 | WO2004113335A2 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
| 12/29/2004 | WO2004113332A1 Nasal preparations |
| 12/29/2004 | WO2004113330A1 Immunosuppressant compounds and compositions |
| 12/29/2004 | WO2004113329A1 Oxazole derivatives as antibacterial agents |
| 12/29/2004 | WO2004113322A1 Processes for the preparation of 1-[(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives |
| 12/29/2004 | WO2004113320A1 Cannabinoid derivatives, methods of making, and use thereof |
| 12/29/2004 | WO2004113319A1 Novel chromene compound |
| 12/29/2004 | WO2004113316A1 Benzofuran inhibitors of factor viia |
| 12/29/2004 | WO2004113312A1 Hydroxamate sulfonamides as cd23 shedding inhibitors |
| 12/29/2004 | WO2004113311A1 Amorphous und crystal forms of (5-chloro-2-{2- |
| 12/29/2004 | WO2004113310A1 Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing |
| 12/29/2004 | WO2004113304A1 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| 12/29/2004 | WO2004113289A2 Glycosidase inhibitors and methods of synthesizing same |
| 12/29/2004 | WO2004113286A2 Mucin synthesis inhibitors |
| 12/29/2004 | WO2004113274A2 Diaryl ureas with kinase inhibiting activity |
| 12/29/2004 | WO2004113270A2 Propionic acid derivatives useful in the treatment of lipid disorders |
| 12/29/2004 | WO2004112864A2 Medical devices and methods for regulating the tissue response to vascular closure devices |